PATENT CLAIM ANALYSIS

Application Number: 16014804
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["435", "325000"]

Abstract:
The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.

Claim (Index 37):
The method of any one of  claims 33 - 36 , wherein the proliferation, activation or increase in the MCV of the engineered T cell occurs in absence of exogenous cytokine or feeder cells.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 94.0
- Lexical Diversity: 1.34615
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14375015', '14412844', '14214728', '15316792', '14997042']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6761210968200517
- 35 USC 102 Novelty (BERT): 0.6162992443374868
- Combined Prediction Score: 0.6701389115717953
- Mean Citation Score: 552.5224499999998
- Max Citation Score: 747.27716
- Similarity Product: 471.15020132152085

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test